Jefferies sets CNY 166.00 target for Mindray stock

Published on 10/16/2026 at 10:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 6.00 percent to CNY 17.747 billion. Mindray stock was last at CNY 167.30 on October 16, 2026, within its CNY 130.66 to CNY 231.49 range.

Growth and valuation in view

Jefferies assigned a CNY 166.00 target on October 13, 2026.
First-half revenue reached CNY 17.747 billion, up 6.00 percent year over year.
Mindray stock was last at CNY 167.30 at 3:04 p.m. CST on Shenzhen on October 16, 2026.
The CNY 130.66 to CNY 231.49 52-week range frames the valuation debate.

Mindray, CNE100003G67, Illustration mit AI erstellt.

Mindray (ISIN CNE100003G67) received a CNY 166.00 price target from Jefferies in a report dated October 13, 2026, according to Moomoo. The call places valuation beside a mixed operating picture for the medical-device maker.

First-half growth was uneven

Mindray generated CNY 17.747 billion of revenue in the first half of 2026, an increase of 6.00 percent from the prior-year period. Net profit attributable to shareholders reached CNY 4.797 billion, down 5.37 percent year over year, while second-quarter revenue rose 10.45 percent to CNY 9.395 billion, according to Futu.

International sales set the tone

Overseas revenue reached CNY 9.471 billion in the first half, up 13.67 percent year over year and equal to 53.00 percent of group revenue. Emerging businesses generated CNY 3.110 billion, up 19.59 percent, giving investors a second growth engine beyond the established portfolio.

What does the target mean for margins?

The answer lies in the contrast between faster sales and weaker reported profit. Medical imaging revenue fell 5.78 percent to CNY 2.836 billion in the first half, while ultra-high-end ultrasound revenue increased by more than 30 percent, according to ChoZan. That mix suggests premium products and international expansion are gaining weight, while procurement pressure and currency effects still influence profitability.

Key dates and valuation frame

Three dated developments define the recent sequence: the half-year report on September 30, 2026, showed CNY 17.747 billion in revenue; the September 2026 launch of the SV70 ventilator expanded Mindray's respiratory-care portfolio; and the October 13, 2026 Jefferies view placed a CNY 166.00 target on the stock. The CNY 130.66 to CNY 231.49 52-week range provides the market frame for that target.

Stock trades in Shenzhen

Mindray was last at CNY 167.30 on the Shenzhen Stock Exchange on October 16, 2026 at 3:04 p.m. CST. Its market capitalization was CNY 202.7 billion on the same date, while the current quotation stood inside the reported 52-week range.